Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
Alicja Krejner‐Bienias, Katarzyna Grzela, Tomasz Grzela
Archivum Immunologiae et Therapiae Experimentalis (2021) Vol. 69, Iss. 1
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Evgeni Gusev, Alexey Sarapultsev, Л. В. Соломатина, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1716-1716
Open Access | Times Cited: 223
Toll-like Receptor 4 in COVID-19: Friend Or foe?
Suprabhat Mukherjee
Future Virology (2022) Vol. 17, Iss. 7, pp. 415-417
Open Access | Times Cited: 44
Therapeutic effects of anti-diabetic drugs on traumatic brain injury
Seyed Mehrad Razavi, Zahra Najafi Arab, Amirhossein Niknejad, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 2, pp. 102949-102949
Closed Access | Times Cited: 6
Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids
Paola Spitalieri, Federica Centofanti, Michela Murdocca, et al.
Cells (2022) Vol. 11, Iss. 7, pp. 1235-1235
Open Access | Times Cited: 28
Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?
Basil Mohammed Alomair, Hayder M. Al‐kuraishy, Ali K. Albuhadily, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 6, pp. 2411-2415
Open Access | Times Cited: 23
Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
Jiaman Du, Jiewen Fu, Wenqian Zhang, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 3
Open Access | Times Cited: 13
Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists
И. И. Дедов, Н. Г. Мокрышева, М. В. Шестакова, et al.
Diabetes Mellitus (2022) Vol. 25, Iss. 1, pp. 27-49
Open Access | Times Cited: 19
Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation
Marina V. Shestakova, O. K. Vikulova, A. R. Elfimova, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 19
The dual role of toll-like receptors in COVID-19: Balancing protective immunity and immunopathogenesis
Payam Behzadi, Deepak Chandran, Chiranjib Chakraborty, et al.
International Journal of Biological Macromolecules (2024), pp. 137836-137836
Closed Access | Times Cited: 4
The High Levels of Soluble Receptors for Tumor Necrosis Factor and Heart Injury in Children with the Pediatric Inflammatory Multisystem Syndrome Associated with Coronavirus Infection: Is This Just a Coincidence? A Proof-of-Concept Study
Maciej Marczak, Alicja Krejner‐Bienias, Agnieszka Jasińska-Nowacka, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 924-924
Open Access
Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients
Zhu Yang, Di Wu, Shanxin Lu, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 34
Open Access | Times Cited: 16
Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection
Weronika Bielka, Agnieszka Przezak, Andrzej Pawlik
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7605-7605
Open Access | Times Cited: 20
COVID-19 and diabetes—Two giants colliding: From pathophysiology to management
Maria Chiara Pelle, Isabella Zaffina, Michele Provenzano, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 13
Narrative review on clinical considerations for patients with diabetes and COVID‐19: More questions than answers
Niki Katsiki, Ricardo Gómez‐Huelgas, Dimitri P. Mikhailidis, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 11
Open Access | Times Cited: 13
Efficacy and Safety of Sitagliptin in the Treatment of COVID-19
Ehab Mudher Mikhael, Siew Chin Ong, Siti Maisharah Sheikh Ghadzi
Journal of Pharmacy Practice (2022) Vol. 36, Iss. 4, pp. 980-987
Open Access | Times Cited: 8
Changes in intestinal morphology, number of mucus-producing cells and expression of coronavirus receptors APN, DPP4, ACE2 and TMPRSS2 in pigs with aging
Waqar Saleem, Xiaolei Ren, Wim Van Den Broeck, et al.
Veterinary Research (2023) Vol. 54, Iss. 1
Open Access | Times Cited: 4
COVID-19 Outcomes and Diabetes Mellitus: A Comprehensive Multicenter Prospective Cohort Study
Karolina Akinosoglou, Georgios Schinas, Evanthia Bletsa, et al.
Microorganisms (2023) Vol. 11, Iss. 6, pp. 1416-1416
Open Access | Times Cited: 4
Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)
José María Mora-Rodríguez, Belén G. Sánchez, Alicia Bort, et al.
Life Sciences (2023) Vol. 336, pp. 122292-122292
Open Access | Times Cited: 4
Systems medicine framework for repurposable drug combinations for COVID-19 comorbidities
S. Saranya, L. Thamanna, P. Chellapandi
Medicine in Omics (2024) Vol. 11, pp. 100038-100038
Open Access | Times Cited: 1
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, et al.
World Journal of Virology (2022) Vol. 11, Iss. 6, pp. 399-410
Open Access | Times Cited: 7
Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
Carlos King Ho Wong, David Tak Wai Lui, Angel Y. C. Lui, et al.
Diabetes & Metabolism (2021) Vol. 48, Iss. 1, pp. 101307-101307
Open Access | Times Cited: 9
The Latest Cellular and Molecular Mechanisms of COVID-19 on Non-Lung Organs
Hamid Askari, Fatemeh Rabiei, Fatemeh Lohrasbi, et al.
Brain Sciences (2023) Vol. 13, Iss. 3, pp. 415-415
Open Access | Times Cited: 3
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
Д. В. Куркин, Д. А. Бакулин, Е. И. Морковин, et al.
Pharmacy & Pharmacology (2023) Vol. 11, Iss. 1, pp. 19-47
Open Access | Times Cited: 3
Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
Xiaohui Wei, Na Rong, Jiangning Liu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 4
Knowledge And Awareness on Various Treatment Modalities of Diabetes Mellitus -A Observational Survey
Sriram Prasath, Palati Sinduja
Journal for Educators Teachers and Trainers (2022) Vol. 13, Iss. 6
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top